Critical analysis of antibacterial agents in clinical development by Theuretzbacher, U, Bush, K, Harbarth, S, Paul, M, Rex, JH, Tacconelli, E, Thwaites, GE

Analysis of the clinical antibacterial and antituberculosis pipeline by Theuretzbacher, U, Gottwalt, S, Beyer, P, Butler, M, Czaplewski, L, Lienhardt, C, Moja, L, Paul, M, Paulin, S, Rex, JH, Silver, LL, Spigelman, M, Thwaites, GE, Paccaud, J-P, Harbarth, S

Reply to Kaye and Belley, “Third-generation cephalosporin-resistant Enterobacterales are critical priority pathogens, too!” by Butler, MS, Gigante, V, Sati, H, Paulin, S, Al-Sulaiman, L, Rex, JH, Fernandes, P, Arias, CA, Paul, M, Thwaites, GE, Czaplewski, L, Alm, RA, Lienhardt, C, Spigelman, M, Silver, LL, Ohmagari, N, Kozlov, R, Harbarth, S, Beyer, P

Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. by Butler, MS, Gigante, V, Sati, H, Paulin, S, Al-Sulaiman, L, Rex, JH, Fernandes, P, Arias, CA, Paul, M, Thwaites, GE, Czaplewski, L, Alm, RA, Lienhardt, C, Spigelman, M, Silver, LL, Ohmagari, N, Kozlov, R, Harbarth, S, Beyer, P